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Abstract
Background and Aims
Early post-transplant hepatic fibrosis is associated with poor outcomes and may be influ-
enced by donor/recipient genetic factors. The rs368234815 IFNL4 polymorphism is related
to the previously described IL28B polymorphism, which predicts etiology-independent
hepatic fibrosis. The aim of this study was to identify the impact of donor and/or recipient
IFNL4 genotype on early fibrosis among patients transplanted for hepatitis C (HCV).
Methods
Clinical data were collected for 302 consecutive patients transplanted for HCV. 116 patients
who had available liver biopsies and donor/recipient DNA were included. 28% of these
patients with stage 2 fibrosis or greater were compared to patients without significant post-
transplant fibrosis with respect to clinical features as well as donor/recipient IFNL4 genotype.
Results
The IFNL4 TT/TT genotype was found in 26.0% of recipients and 38.6% of donors. Patients
who developed early post-transplant fibrosis had a 3.45 adjusted odds of having donor
IFNL4 TT/TT genotype (p = 0.012). Donor IFNL4 TT/TT genotype also predicted decreased
overall survival compared to non-TT/TT genotypes (p = 0.016).
Conclusions
Donor IFNL4 TT/TT genotype, a favorable predictor of spontaneous HCV clearance pre-
transplant, is associated with increased early post-transplant fibrosis and decreased survival.
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Introduction
End-stage liver disease attributable to chronic HCV infection remains a leading indication for
liver transplantation [1]. Some patients develop hepatic fibrosis early after transplant, and this
may contribute to graft failure in a subset of patients. The degree of post-transplant fibrosis
varies from person to person and genetic factors play an important role in disease progression
[2]. A single nucleotide polymorphism (rs12979860) upstream of the interferon lambda 3 gene
(IFNL3, IL28B) has been shown to predict post-transplant fibrosis and fibrosing cholestatic
hepatitis in the absence of treatment [3,4]. While the IL28B C/C genotype is associated with
increased spontaneous clearance of HCV and favorable treatment response, patients who
receive a liver with the C/C genotype in the transplant setting have higher rates of histologic
recurrence and fibrosis [5].
Subsequent studies have identified a novel dinucleotide polymorphism (ss469415590
also called rs368234815, TT/ΔG) that is strongly associated with spontaneous HCV clear-
ance and is found in strong linkage disequilibrium with rs12979860 [6]. The dinucleotide
variant is located 367bp upstream of rs12979860 and is comprised of a one-base deletion
polymorphism (loss of T) and a one-base substitution variant (T>G) [6]. The TT/TT geno-
type is associated with increased spontaneous HCV clearance relative to the ΔG/ΔG geno-
type [6]. The identification of the rs368234815 polymorphism is particularly interesting as
it suggests a possible molecular mechanism underlying its predictive value for viral clear-
ance. The ΔG frame-shift variant creates a novel gene, IFNL4, which is transiently activated
in response to HCV infection [6]. IFNL4 encodes a protein which induces phosphorylation
and activation of STAT1 and STAT2, activating downstream interferon-stimulated
response elements (ISRE). This leads to activation of interferon-stimulated genes (ISGs) in
a manner similar to type I and type III interferon signaling, generating an antiviral response
in hepatocytes [6].
Studies have shown that IFNL4 polymorphisms are a predictor of treatment response with
interferon-based regimens with genotype 2 and 3 as well as for simeprevir and interferon-
based therapy for genotype 1 [7–9]. In addition, polymorphisms in both IFNL3 and IFNL4
have been shown to be associated with high serum and hepatic iron concentrations [10].
Though there is only a weak association between response to direct active anti-viral therapy
(DAA) and IFNL4, the presence of the beneficial IFNL4 polymorphisms were associated with
higher prevalence of the NS5A Y93H resistance associated variant (RAV) [11,12]. In the con-
text of liver transplantation, IFNL4 polymorphisms have been shown to be associated with sus-
tained viral response (SVR) to interferon-based regimens, with recipient IFNL4 TT/TT
genotype being associated with higher SVR rates [13].
The impact of IFNL4 polymorphisms on hepatic fibrosis has not been studied in the context
of transplant. The aim of this study was to study the impact of donor and recipient
rs368234815 genotype on early post-transplant fibrosis in treatment naïve patients. Based on
observations in IL28B, we hypothesized that donor rs368234815 TT/TT genotype, a predictor
of spontaneous viral clearance in the pre-transplant setting, is associated increased inflamma-
tion and early post-transplant fibrosis.
Patients and Methods
Patients
We collected clinical data for 302 consecutive patients who underwent liver transplant at
Cleveland Clinic (Cleveland, OH) for chronic HCV from January 1, 2006 to December 31,
2011. We chose patients prior to the routine use of interferon free direct anti-viral treatments
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as these patients underwent routine surveillance protocol liver biopsies. Patients who did not
have available donor/recipient DNA or liver biopsy between 6–18 months were excluded. All
patients were followed up according to a standard protocol. The study protocol conformed to
the ethical guidelines of the 1975 Declaration of Helsinki and 2008 Declaration of Istanbul and
was approved by the Institutional Review Board at Cleveland Clinic. Written consent for the
storage of tissue specimens and clinical data for research purposes was obtained for each
patient in accordance with the Institutional Review Board at Cleveland Clinic. None of the
transplant donors were from a vulnerable population and all donors or next of kin provided
written informed consent that was freely given.
Patients underwent protocol liver biopsies at 6 months and 1 year post-transplantation and
yearly thereafter. Treatment was generally only offered to patients with biopsy-proven fibrosis.
As such, few patients underwent treatment prior to first biopsy. Liver biopsies performed
between 6–18 months post-transplant were graded and staged according to Batts and Ludwig
criteria [14]. A previously accepted cutoff of Batts and Ludwig stage 2–4 was defined as signifi-
cant fibrosis [15]. Donor and recipient genotypes were compared among patients who devel-
oped significant fibrosis on any protocol biopsy between 6–18 months and patients with mild
or no fibrosis. Additional clinical variables were obtained from a prospectively maintained
database of patients receiving liver transplants at Cleveland Clinic. HCV genotyping was per-
formed using the line probe assay in all patients.
DNA Collection and Genotyping
Donor and recipient DNA was extracted from whole blood obtained and stored at the time of
transplant according to standard protocol. The rs12979860 polymorphism was analyzed by
TaqMan SNP genotyping assay (Life Technologies, Carlsbad, CA). The C allele was detected
using a VIC-labeled probe with the sequence TGGTTCGCGCCTTC and T allele was detected
using a FAM-labeled probe with the sequence CTGGTTCACGCCTTC [6]. The rs368234815
polymorphism was analyzed in the same manner. The TT allele was detected using a VIC-
labeled probe with the sequence ATCGCAGAAGGCC and ΔG allele was detected using a
FAM-labeled probe with the sequence ATCGCAGCGGCCC [6].
Statistical Analysis
Data are presented as mean ± standard deviation, median [25th, 75th percentiles] or N (%). The
prevalence of ss469425590 genotypes among donor and recipients was estimated by calculat-
ing the percentage of patients with ΔG/ΔG, TT/ΔG and TT/TT. A univariable analysis was per-
formed to assess factors associated with developing fibrosis stage 2–4 post-transplant;
Pearson’s chi-square tests were used for categorical variables and analysis of variance
(ANOVA) or the non-parametric Kruskal-Wallis tests were used for continuous or ordinal
factors. In addition, multivariable logistic regression was performed to assess association
between genotype and presence of moderate fibrosis after adjusting for potential confounders;
fibrosis 2–4 was modeled as the outcome with ss469424590 genotype and other clinical charac-
teristics as the independent variables. Survival analysis was also performed. Follow-up time
was defined as months from OLT to death and subjects who remained alive were censored on
7/1/2013. Kaplan-Meier plots were constructed and log-rank tests were used to compare the
genotypes. A p<0.05 was considered statistically significant. SAS (version 9.3, The SAS Insti-
tute, Cary, NC) and R (version 3.0.3, The R Foundation for Statistical Computing, Vienna,
Austria) were used to perform all analyses.
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Results
Patient Characteristics
Clinical data were collected for a total of 302 consecutive patients who were transplanted for
HCV during the study period. 116 patients who had available donor DNA, recipient DNA,
and liver biopsy between 6–18 months were included in the analysis (Fig 1). The study popula-
tion was similar to the overall transplant recipient population for HCV at Cleveland Clinic,
74% were males and 19.3% were African Americans. 33 patients developed significant fibrosis
on liver biopsy (28%), which is consistent with previous reports [5]. The mean time from
transplant to biopsy was 10.7 ± 2.4 months; there was no difference in follow-up time between
those who progressed to stage 2–4 and those who did not (p = 0.90).
Table 1 shows the donor and recipient characteristics for patients with and without signifi-
cant fibrosis. Patients with significant fibrosis were more likely to be African American, which
is consistent with previously observed racial variation in HCV progression. There was no sig-
nificant difference in recipient age, recipient gender, HCV genotype, donor age, cold ischemia
time, or donor risk index (DRI) among the 2 groups.
Distribution of Genotypes
The distribution of genotypes for the rs368234815 and rs12979860 polymorphisms among 116
included patients is shown in Table 2. In 2 patients the recipient rs368234815 genotype could
not be determined and in 12 patients the donor rs368234815 genotype could not be deter-
mined. There were no significant differences between groups for unadjusted comparison. The
linked rs368234815 and rs12979860 polymorphisms demonstrated similar allele distributions
for the donor and recipient population.
rs368234815 Genotype and Fibrosis
The rs368234815 TT/TT genotype was found in 38.6% of donors and 26.0% of recipients. On
univariable analysis, recipient race [African American] and donor TT/TT were found to be
significantly associated with fibrosis. The donor or recipient rs12979860 (IL28B) polymor-
phism was not a significant predictor of early post-transplant fibrosis on univariable analysis.
On multivariable analysis adjusting for African American race and pre-transplant HCC,
donor TT/TT genotype was associated with a 3.45 odds of developing fibrosis (Table 3). No
other comparisons were found to be significant.
Patients who developed significant fibrosis had a higher proportion of African Americans.
Therefore, we also analyzed the impact of the two polymorphisms in the African American
recipient population of our cohort. In this cohort, the donor TT/TT genotype trended towards
a higher odds (6.8) of developing fibrosis but the comparisons were not statistically significant
due to relatively low numbers (p = 0.085).
Survival Analysis
The Kaplan-Meier plots for post-transplant survival for rs368234815 genotype and rs12979860
genotype are presented in Fig 2. Subjects with a donor that had rs368234815 TT/TT genotype
had significantly worse survival than those with rs368234815 non-TT/TT donors (p = 0.016).
There was no significant difference for recipient rs368234815 genotype or donor/recipient
rs12979860 genotype. When survival was compared for donor/recipient rs36823481 combina-
tions, a trend toward shorter survival was observed in non-TT/TT recipients who received a
liver from a donor with TT/TT genotype (S1 Fig).
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Fig 1. Identification of Patient Population.
doi:10.1371/journal.pone.0166998.g001
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Discussion
We evaluated the potential association between rs368234815 genotype and post-transplant
fibrosis in patients who underwent liver transplant for HCV cirrhosis. We show that in our
cohort, patients who developed early post-transplant fibrosis had a 3.45 adjusted odds of hav-
ing donor IFNL4 TT/TT genotype (p = 0.012, Table 3).These findings are consistent with the
linked rs12979860 IFNL3 polymorphism (IL28B), where the favorable C/C genotype predicts
increased post-transplant fibrosis when acquired in the donor liver [2,5]. However, in regards
to post-transplant fibrosis, the donor IFNL4 genotype achieved significance, while recipient
and donor IFNL3 genotype did not (Table 3).
The IFNL3 rs12979860 (IL28B) polymorphism was first identified as being predictive of
treatment response in the non-transplant setting, with the C/C genotype being associated with
a higher probability of achieving SVR to interferon-based regimens [16]. This finding was con-
firmed in subsequent studies in the transplant setting, with donor C/C genotype being associ-
ated with higher SVR rates following transplant [2]. However, the donor C/C genotype was
also found to be associated with increased early HCV-related fibrosis following transplant [5].
With the identification of the IFNL4 TT/TT genotype as a potentially stronger predictor of
SVR in the non-transplant setting, the present study was conducted to in order to confirm the
suspected association of the donor IFNL4 polymorphism with early post-transplant fibrosis
[6]. Our finding that donor IFNL4 TT/TT genotype is associated with significant fibrosis is
therefore consistent with previous observations with regards to IFNL3. Confirmation of this
finding is important as the functional role of IFNL4 is studied further at the basic science level
and in the context of HCV-independent hepatic fibrosis.
The functional role of the IFNL4 rs368234815 allows speculation regarding the potential
mechanism of increased fibrosis among patients who receive a liver with the TT/TT allele. The
Table 1. Patient Characteristics.
Factor Fibrosis 2-4(N = 33) Fibrosis 0–1 (N = 83) p-value
Recipient Age at Transplant 54.9±6.6 56.2±6.3 0.33a
Recipient Male Sex 24 (72.7%) 62 (74.7%) 0.83c
Recipient African-American 13 (40.6%) 8(10.4%) 0.001c
Recipient CMV+ 25 (75.8%) 59 (71.1%) 0.61c
Diagnosis 0.090c
. HCV 11 (33.3%) 19 (22.9%)
. HCV + alcohol 7 (21.2%) 14 (16.9%)
. HCV + HCC 11 (33.3%) 42 (50.6%)
. HCV + alcohol + HCC 1 (3.0%) 7 (8.4%)
. HCV + Other 3 (9.1%) 1 (1.2%)
HCV Genotype 0.12c
. 1 29 (87.9%) 50 (65.8%)
. 2 1 (3.0%) 7 (9.2%)
. 3 2 (6.1%) 15 (19.7%)
. 4 1 (3.0%) 4 (5.3)
Donor Age at Death 39.5±15.2 40.5±13.8 0.73a
Cold-Ischemia Time 7.6±1.7 7.2±1.7 0.38a
Donor Risk Index 2.1±0.51 2.1±0.49 0.68a
Values presented as Mean ± SD or N (%).
p-values: a = ANOVA, c = Pearson’s chi-square test.
doi:10.1371/journal.pone.0166998.t001
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TT/TT allele introduces a frame-shift mutation that leads to no expression of IFNL4 [6]. The
lack of IFNL4 expression results in decreased expression of ISGs in liver tissues from patients
with chronic HCV [17]. It is possible that in patients with donor rs368234815 TT/TT geno-
type, decreased expression of ISGs is associated with increased progression to fibrosis in the
setting of recurrent hepatitis C. Conversely, IFNL3 polymorphisms have been shown to be
associated with etiology-independent hepatic fibrosis, suggesting that the mechanism underly-
ing the association between IFNL4 TT/TT genotype and post-transplant fibrosis might be
HCV-independent [15]. Further investigation of IFNL4 genotype in non-HCV transplant
cohorts might clarify the dependence of the observed association on HCV-recurrence. Finally,
it is also possible that the association between the favorable IFNL4 polymorphism and preva-
lence of resistance associated variants may explain the increased progression to fibrosis [11].
Though we are in the era of near universal cure with currently available direct antiviral regi-
mens, our data remains clinically relevant in the setting of liver transplantation. Many subjects
with chronic hepatitis C and decompensated cirrhosis are not treated pre-transplant. This is
because successful cure of hepatitis C may place these patients in a so called “liver purgatory”
where they remain on the transplant waitlist with a decrease in MELD scores without
Table 2. Allele Frequency for Patient Population.
Overall Fibrosis 2–4 Fibrosis 0–1
(N = 116) (N = 33) (N = 83)
Factor n n n p-value
Donor rs368234815 114 32 82 0.094
. TT/TT 44 (38.6%) 17 (53.1%) 27 (32.9%)
. TT/ΔG 49 (43.0%) 12 (37.5%) 37 (45.1%)
. ΔG/ΔG 21 (18.4%) 3 (9.4%) 18 (22.0%)
Recipient rs368234815 104 31 73 0.07
. TT/TT 27 (26.0%) 4 (12.9%) 23 (31.5%)
. TT/ΔG 52 (50.0%) 16 (51.6%) 36 (49.3%)
. ΔG/ΔG 25 (24.0%) 11 (35.5%) 14 (19.2%)
Donor rs12979860 116 33 83 0.26
. C/C 48 (41.4%) 17 (51.5%) 31 (37.3%)
. C/T 49 (42.2%) 13 (39.4%) 36 (43.4%)
. T/T 19 (16.4%) 3 (9.1%) 16 (19.3%)
Recipient rs12979860 116 33 83 0.25
. C/C 30 (25.9%) 5 (15.2%) 25 (30.1%)
. C/T 61(52.6%) 20 (60.6%) 41 (49.4%)
. T/T 25 (21.6%) 8 (24.2%) 17 (20.5%)
Values presented as N (column %) with Pearson’s chi-square test.
doi:10.1371/journal.pone.0166998.t002
Table 3. Adjusted Comparison of Genotypes.
Genotype Unadjusted OR p-value Adjusted*OR p-value
Donor rs368234815: TT/TT vs non-TT/TT 2.33 (1.01, 5.26) 0.049 3.45 (1.32, 9.09) 0.012
Recipient rs368234815: TT/TT vs non-TT/TT 0.32 (0.10, 1.03) 0.056 0.53 (0.15, 1.82) 0.3
Donor rs12979860: CC vs non-CC 1.79 (0.77, 4.00) 0.16 2.38 (0.94, 6.25) 0.067
Recipient rs12979860: CC vs non-CC 0.42 (0.14, 1.19) 0.10 0.45 (0.14, 1.47) 0.19
* Recipient and donor genotypes are adjusted for recipient African-American vs. non-African-American race and recipient diagnosis (HCC vs no-HCC).
doi:10.1371/journal.pone.0166998.t003
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significant clinical improvement. Pre-transplant cure of hepatitis C may also preclude them
from receiving hepatitis C positive grafts. Therefore many transplant centers are waiting until
after transplantation to initiate anti-viral treatment. As viremic patients continue to receive
transplants and payers refuse coverage for DAA in the early post-transplant period, genetic
factors that lead to rapid progression of fibrosis may help to identify patents requiring early
therapy. Moreover, in subjects who receive the rs368234815 TT/TT genotype through trans-
plantation, the increased risk of NS5A RAVs may be detrimental.
We recognize several limitations in the present study. Exclusion of patients who did not
have donor or recipient DNA or a liver biopsy performed between 6–18 months has the
Fig 2. Kaplan-Meier curves for donor/recipient rs368234815 genotype and donor/recipeient rs12979860 genotype.
doi:10.1371/journal.pone.0166998.g002
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potential of selection bias. However, we separately analyzed baseline characteristics among the
study population and the total population of transplanted patients and found no significant dif-
ferences. Though it would be ideal to perform a genome wide association study, the sample size
limited us to explore specific polymorphisms based on our hypothesis regarding specific genetic
polymorphisms. The sample size may have also contributed to the lack of a significant associa-
tion between IFNL3 genotype and fibrosis, a finding that has been observed in multiple larger
studies [2,5]. In addition, the enrichment of African Americans among the patients with signifi-
cant fibrosis may impact the relative distribution of polymorphisms. However, the trends appear
to be similar when the African Americans in our cohort were analyzed separately, though num-
bers limit the ability to adequately interpret sub-groups analysis. Similarly, genotype 1 HCV has
been associated with increased fibrosis following liver transplantation and a non-significant
trend toward more genotype 1 patients in the fibrosis group was observed in this study [18]. As
such, HCV genotype represents an additional potential confounder in addition to race.
Early HCV-related fibrosis following liver transplantation is associated with risk of graft
loss. Even in the era of direct acting anti-viral treatment, many patients with decompensated
cirrhosis are now being treated post-transplant and donor genetic markers may be a useful
tool to predict patients who are at risk to develop early post-transplant fibrosis. More impor-
tantly, this data offers insight into the role of novel donor genetic factors in post-transplant
fibrosis in HCV.
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